HeartSciences reports passing of COO Mark Hilz, will not seek immediate replacement

HeartSciences COO and director Mark Hilz died on April 1 at age 67; he served on the board since 2013 and as COO and Corporate Secretary since March 2022. The company does not plan to appoint a new COO in the foreseeable future and expects no changes to operations or the planned commercialization of its MyoVista Insights software and MyoVista wavECG device. The MyoVista wavECG was submitted to the U.S. FDA for 510(k) premarket clearance in December 2025; HeartSciences trades on NASDAQ under HSCS and HSCSW.

Analysis

The decision not to refill the COO role materially raises execution and governance risk for a small-cap medtech at a critical regulatory/commercial inflection. Absent a dedicated operator, tasks that typically accelerate time-to-market—supplier qualification, quality systems, payer contracting and launch logistics—are more likely to be delayed or shifted to outside vendors, increasing cash burn and vendor bargaining power by an estimated 10-30% in contract premium versus an integrated in-house path.

Second-order winners include contract manufacturers, regulatory consultancies and commercialization-focused CROs that can plug the operational gap quickly; larger, well-capitalized device incumbents with established go-to-market channels also gain strategic optionality to capture share if this company slips. Short-term market dynamics favor active volatility players and warrant holders who can arbitrage dilutive financing expectations, while long-biased institutional holders should flag concentrated position governance risk.

Timeline and catalysts: expect an immediate sentiment move (days–weeks) as holders reassess staffing risk and liquidity; within 1–6 months the stock’s direction will hinge on either a hire/partner announcement or visible progress on regulatory interactions—absent those, plan for a 6–12 month erosion scenario driven by extended commercialization timelines and potential bridge financing. A clear reversal catalyst is the appointment of a senior medtech commercial/regulatory executive or a non-dilutive OEM/distribution partnership, which historically restores 30–60% of lost market cap for similar microcaps within 3 months.

From a risk-management perspective, the path to upside is binary and event-driven; downside is gradual but amplifies when cash runway and regulatory timelines overlap. Monitor vendor contracts, FDA interaction summaries, and any proxy/filing language about delegated responsibilities—those three datapoints will move the stock materially ahead of product milestones.

Key Decisions for Investors

• Short HSCS equity (3–6 month horizon): initiate a modest-sized short (max 1–2% portfolio risk) expecting 15–30% downside if no senior hire or partner is announced within 90 days; place a hard stop at 10% adverse move and re-evaluate on any management update.
• Buy HSCS Jan 2027 put spread (bear put spread): buy puts at-the-money and sell lower strikes to cap cost, targeting 3:1 downside skew versus premium paid — use if you expect regulatory/commercial delays but want defined risk for 6–18 month event risk.
• Pair trade — short HSCS / long IHI (iShares U.S. Medical Devices ETF) (6–12 months): hedge sector exposure while expressing company-specific execution risk; size 1:1 notional with stop-loss if HSCS announces a seasoned commercial/regulatory hire.
• Event-driven long (conditional): if management announces an experienced medtech COO or a non-dilutive OEM distribution agreement, rotate into HSCS equity or buy LEAP calls (12–18 month expiries) with a 2:1 upside/downside target, taking profits as FDA/clearance milestones are met.
• For existing holders: sell near-term covered calls or buy out-of-the-money protective puts to monetize high implied volatility and cap downside over the next 3–6 months while awaiting clarity on operational leadership.